To include your compound in the COVID-19 Resource Center, submit it here.
Texas Biotechnology Corp.
D. Blech & Co. analyst Michael King initiated coverage with a "buy" and a one-year price target of
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury